Osimertinib-Savolitinib Beats Chemotherapy After EGFR-TKI Progression

A phase 3 trial (SAFFRON) compared osimertinib plus savolitinib with platinum-pemetrexed in patients with EGFR-mutated advanced NSCLC with MET overexpression or amplification whose disease progressed on osimertinib. The combination significantly improved progression-free survival (hazard ratio 0.55) and overall survival (hazard ratio 0.68) compared with chemotherapy, with 12-month progression-free survival of 36% versus 10% and overall survival of 70% versus 53%. Grade 3 or higher adverse events occurred in 64% of the combination group and 63% of the chemotherapy group, with peripheral edema, anemia, and diarrhea most frequently reported in the combination arm.

Most relevant for: Patients with EGFR-mutated advanced non-small-cell lung cancer with MET overexpression or amplification whose disease has progressed during osimertinib therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.